<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Clozapine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00363</strong>&#160; (APRD00470)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00363/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00363/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00363.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00363.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00363.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00363.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00363.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00363">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Clozapin</td><td>German</td><td>Ph. Eur. 7</td></tr><tr><td>Clozapine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>DCF, USAN, BAN</td></tr><tr><td>Clozapinum</td><td>Latin</td><td>Ph. Eur. 7</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Azaleptine</td><td>Arpimed</td></tr><tr><td>Chlorpromazine</td><td>Pfoshen</td></tr><tr><td>Cloment</td><td>Pharmaplan</td></tr><tr><td>Clonex</td><td>Adeka</td></tr><tr><td>Clopin</td><td>East West</td></tr><tr><td>Clopine</td><td>Douglas</td></tr><tr><td>Clopsine</td><td>Psicofarma</td></tr><tr><td>Clorazem</td><td>Remedica</td></tr><tr><td>Clozapine</td><td>Remedica</td></tr><tr><td>Clozaril</td><td>Novartis</td></tr><tr><td>FazaClo</td><td>Jazz Pharmaceuticals</td></tr><tr><td>Lanolept</td><td>Lannacher</td></tr><tr><td>Lapenax</td><td>Novartis</td></tr><tr><td>Leponex</td><td>Novartis</td></tr><tr><td>Lodux</td><td>Rider</td></tr><tr><td>Lozapin</td><td>Torrent</td></tr><tr><td>Luften</td><td>Pharos</td></tr><tr><td>Mezapin</td><td>Panbiotic</td></tr><tr><td>Refract</td><td>Crescent</td></tr><tr><td>Refraxol</td><td>AC Farma</td></tr><tr><td>Sensipin</td><td>Beximco</td></tr><tr><td>Sequax</td><td>Ivax</td></tr><tr><td>Sizopin</td><td>Sun</td></tr><tr><td>Sizopril</td><td>Meprofarm</td></tr><tr><td>Syclop</td><td>Brown &amp; Burk Phils</td></tr><tr><td>Syzopin</td><td>Psyco Remedies</td></tr><tr><td>Tanyl</td><td>Novamed</td></tr><tr><td>Uspen</td><td>Yu Sheng</td></tr><tr><td>VERSACLOZ</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zapen</td><td>Psipharma</td></tr><tr><td>Zapenia</td><td>Incepta</td></tr><tr><td>Zapine</td><td>Taiwan Biotech</td></tr><tr><td>Ziproc</td><td>Torrent</td></tr><tr><td>Zopin</td><td>Psychotropics India</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antipsychotic-agents">Antipsychotic Agents</a></li>
<li><a href="/mesh/serotonin-antagonists">Serotonin Antagonists</a></li>
<li><a href="/mesh/gaba-antagonists">GABA Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>5786-21-0</td></tr><tr><th>Weight</th><td>Average: 326.823<br>Monoisotopic: 326.129824335</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>19</sub>ClN<sub>4</sub></td></tr><tr><th>InChI Key</th><td>QZUDBNBUXVUHMW-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">6-chloro-10-(4-methylpiperazin-1-yl)-2,9-diazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN1CCN(CC1)C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzodiazepines</td></tr><tr><th>Subclass</th><td>Dibenzodiazepines</td></tr><tr><th>Direct parent</th><td>Dibenzodiazepines</td></tr><tr><th>Alternative parents</th><td>Chlorobenzenes; Aryl Chlorides; Diazinanes; Piperazines; Tertiary Amines; Polyamines; Carboxamidines; Secondary Amines; Organochlorides</td></tr><tr><th>Substituents</th><td>chlorobenzene; aryl halide; aryl chloride; 1,4-diazinane; benzene; piperazine; tertiary amine; amidine; polyamine; carboxylic acid amidine; secondary amine; organohalogen; organochloride; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the dibenzodiazepines. These are compounds containing a dibenzodiazepine moiety, which consists of two benzene connected by a diazepine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in patients with treatment-resistant schizophrenia.</td></tr><tr><th>Pharmacodynamics</th><td>Clozapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Clozapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT<sub>2</sub>), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Clozapine acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT<sub>2</sub> with similar receptor affinities may explain some of the other therapeutic and side effects of Clozapine. Clozapine's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Clozapine's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Clozapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.</td></tr><tr><th>Mechanism of action</th><td>Clozapine's antipsychotic action is likely mediated through a combination of antogistic effects at D2 receptors in the mesolimbic pathway and 5-HT2A receptors in the frontal cortex. D2 antagonism relieves positive symptoms while 5-HT2A antagonism alleviates negative symptoms.</td></tr><tr><th>Absorption</th><td>Rapid and almost complete</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>97% (bound to serum proteins)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Clozapine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00100">Norclozapine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/100">Details</a></td></tr><tr><td>Clozapine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003606" target="_blank">Dimethylaniline monooxygenase [N-oxide-forming] 3</a></li></ul></td><td><a href="/metabolites/DBMET00101">Clozapine N-oxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/101">Details</a></td></tr><tr><td>Clozapine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003544" target="_blank">UDP-glucuronosyltransferase 1-4</a></li></ul></td><td><a href="/metabolites/DBMET00102">Clozapine glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/102">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Approximately 50% of the administered dose is excreted in the urine and 30% in the feces.</td></tr><tr><th>Half life</th><td>8 hours (range 4-12 hours)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Clozapine carries a black-box warning for agranulocytosis.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3<br>Gene symbol: GNB3<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P16520" target="_blank">P16520 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs5443" target="_blank">rs5443 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>TT allele</td><td>Schizophrenia patients taking this drug more more weight than patients with at least one rs5443(c) allele</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16141801" target="_blank" title='# Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ: C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet Genomics. 2005 Oct;15(10):743-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16141801'>16141801 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9904</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9614</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6151</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8684</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.6791</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.7407</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.8049</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7509</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6088</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5722</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9432</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9137</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.571</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9106
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.0838 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8189
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7164
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Azur pharma international iii ltd</li>
<li>Caraco pharmaceutical laboratories ltd</li>
<li>Ivax pharmaceuticals inc sub teva pharmaceuticals usa</li>
<li>Mylan pharmaceuticals inc</li>
<li>Par pharmaceutical</li>
<li>Sandoz inc</li>
<li>Novartis pharmaceuticals corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Alamo Pharmaceuticals LLC</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.avanir.com">Avanir Pharmaceuticals</a></li>
<li><a href="http://www.azurpharma.com">AzurPharma Inc.</a></li>
<li><a href="http://www.caraco.com">Caraco Pharmaceutical Labs</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.cimalabs.com">Cima Laboratories Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li>Ivax Pharmaceuticals</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05773">ado-trastuzumab emtansine</a></td><td>Avoid combination due to the increased potential for agranulocytosis. </td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Bromazepam may increase the adverse effects of clozapine. Consider alternate therapy or a reduction in the bromazepam dose. Monitor for respiratory depression and hypotension if concomitant therapy is initiated.</td></tr><tr><td><a href="/drugs/DB00201">Caffeine</a></td><td>Caffeine increases the effect and toxicity of clozapine</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine may decrease the serum concentration of clozapine by increasing its metabolism. Concomitant therapy should also be avoided due to increased risk of bone marrow suppression. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00475">Chlordiazepoxide</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine may increase the serum concentratin of clozapine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if cimetidine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01594">Cinolazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00537">Ciprofloxacin</a></td><td>Ciprofloxacin may increase clozapine serum levels</td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>The antidepressant increases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB00349">Clobazam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01068">Clonazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00628">Clorazepate</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01551">Dihydrocodeine</a></td><td>CNS depressants may enhance the adverse effects and toxicity of other CNS depressants. It is recommended to monitor therapy. </td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Erythromycin increases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB01215">Estazolam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Hydantoin decreases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB01544">Flunitrazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>The antidepressant increases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB00690">Flurazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00176">Fluvoxamine</a></td><td>The antidepressant increases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Hydantoin decreases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00801">Halazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Clozapine, a moderate CYP2D6 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive CNS despresant and anticholinergic effects may also occur. Monitor for changes in the therapeutic and adverse effects of haloperidol if clozapine is initiated, discontinued or dose changed. Also monitor for increased CNS depressant and anticholinergic effects during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>Erythromycin increases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB01587">Ketazolam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00555">Lamotrigine</a></td><td>Lamotrigine increases the effect and toxicity of clozapine</td></tr><tr><td><a href="/drugs/DB00186">Lorazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Hydantoin decreases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00745">Modafinil</a></td><td>Modafinil increases the effect and toxicity of clozapine</td></tr><tr><td><a href="/drugs/DB01595">Nitrazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01059">Norfloxacin</a></td><td>Ciprofloxacin may increase clozapine serum levels</td></tr><tr><td><a href="/drugs/DB00842">Oxazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01229">Paclitaxel</a></td><td>Avoid combination due to the potential enhancement of agranulocytosis by clozapine. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin may decrease the effect of clozapine.</td></tr><tr><td><a href="/drugs/DB01588">Prazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB01589">Quazepam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin decreases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin decreases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir increases the effect and toxicity of clozapine</td></tr><tr><td><a href="/drugs/DB00989">Rivastigmine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01104">Sertraline</a></td><td>The antidepressant increases the effect of clozapine</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Clozapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Clozapine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Clozapine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clozapine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00231">Temazepam</a></td><td>The benzodiazepine, Temazepam, may increase the adverse effects of Clozapine. Monitor for respiratory depression and hypotension if concomitant therapy is initiated. </td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. </td></tr><tr><td><a href="/drugs/DB00730">Thiabendazole</a></td><td>The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clozapine by decreasing Clozapine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clozapine if Thiabendazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Avoid combination due to the increased risk of clozapine induced agranulocytosis. 
</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Clozapine may decrease the effect of Tramadol by decreasing active metabolite production. 
</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>Trimethobenzamide and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB06684">Vilazodone</a></td><td>Selective Serotonin Reuptake Inhibitors may decrease the metabolism of clozapine. If concurrent use of these agents is employed, monitor for increased toxic effects of clozapine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased effects if a SSRI is discontinued/dose decreased.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Limit caffeine intake (may reduce clozapine matabolism).</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>